Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Cardiff Oncology, Inc.CRDF · Entity 6917 | Director | June 11, 2026 | June 16, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Cardiff Oncology, Inc.
Report date June 11, 2026 · Filed June 16, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock OptionsSEC Table II · derivative / convertible security · Conversion / exercise price $1.59 · Expires 2036-06-11 | Direct | 263,430 |
Reported balance
After 2026-06-11 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-11 · Grant · Acquired 40,565 · Balance 263,430 |
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 11, 2026 Filed Jun 16, 2026 01:30 UTC | Cardiff Oncology, Inc. CRDF · Entity 6917 | GrantStock Options · Derivative | 40,565 | $0.00 Strike: $1.59 | $0.00 |
DisclosureSEC source: 0001393415-26-000002 · ownership.xml · derivative · entry 1 Markin Rodney S · CIK 0001393415 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 263,430 Underlying: Common Stock · 40,565 shares Expires 2036-06-11 Read SEC document |
| June 26, 2025 Filed Jun 30, 2025 13:38 UTC | Cardiff Oncology, Inc. CRDF · Entity 6917 | GrantStock Options · Derivative | 40,565 | $0.00 Strike: $3.16 | $0.00 |
DisclosureSEC source: 0001641172-25-017071 · ownership.xml · derivative · entry 1 Markin Rodney S · CIK 0001393415 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 222,865 Underlying: Common Stock · 40,565 shares Expires 2035-06-26 Read SEC document |
| June 27, 2024 Filed Jul 1, 2024 20:08 UTC | Cardiff Oncology, Inc. CRDF · Entity 6917 | GrantStock Options · Derivative | 29,700 | $0.00 Strike: $2.33 | $0.00 |
DisclosureSEC source: 0001628280-24-030636 · wk-form4_1719864512.xml · derivative · entry 1 Markin Rodney S · CIK 0001393415 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 182,027 Underlying: Common Stock · 29,700 shares Expires 2034-06-27 Read SEC document |
| June 15, 2023 Filed Jun 20, 2023 21:08 UTC | Cardiff Oncology, Inc. CRDF · Entity 6917 | GrantStock Options · Derivative | 27,700 | $0.00 Strike: $1.59 | $0.00 |
DisclosureSEC source: 0001628280-23-022742 · wk-form4_1687295269.xml · derivative · entry 1 Markin Rodney S · CIK 0001393415 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 152,327 Underlying: Common Stock · 27,700 shares Expires 2033-06-15 Read SEC document |
| March 09, 2022 Filed Mar 10, 2022 23:41 UTC | Cardiff Oncology, Inc. CRDF · Entity 6917 | GrantStock Options · Derivative | 26,800 | $0.00 Strike: $2.50 | $0.00 |
DisclosureSEC source: 0001628280-22-005793 · wf-form4_164695568373039.xml · derivative · entry 1 Markin Rodney S · CIK 0001393415 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 124,627 Underlying: Stock Options · 26,800 shares Expires 2032-03-09 Read SEC document |
| June 10, 2021 Filed Jun 14, 2021 20:12 UTC | Cardiff Oncology, Inc. CRDF · Entity 6917 | GrantStock Options · Derivative | 22,000 | $0.00 Strike: $7.98 | $0.00 |
DisclosureSEC source: 0001628280-21-012174 · wf-form4_162370153475601.xml · derivative · entry 1 Markin Rodney S · CIK 0001393415 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 97,827 Underlying: Common Stock · 22,000 shares Expires 2031-06-10 Read SEC document |
| March 26, 2021 Filed Mar 29, 2021 17:38 UTC | Cardiff Oncology, Inc. CRDF · Entity 6917 | PurchaseCommon Stock | 2,900 | $10.32 | $29,933.22 |
DisclosureSEC source: 0001628280-21-005926 · wf-form4_161703951417179.xml · nonDerivative · entry 1 Markin Rodney S · CIK 0001393415 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · Fund Disclosed balance after: 23,879 F1 · ownership.nature: Through Prairie Ventures, LLC Read SEC document |
| June 17, 2020 Filed Jun 19, 2020 20:15 UTC | Cardiff Oncology, Inc. CRDF · Entity 6917 | GrantStock Options · Derivative | 28,858 | $0.00 Strike: $2.60 | $0.00 |
DisclosureSEC source: 0001104659-20-075232 · a4.xml · derivative · entry 1 Markin Rodney S · CIK 0001393415 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,827 Underlying: Common Stock · 28,858 shares Expires 2030-06-17 Read SEC document |
| May 14, 2020 Filed May 18, 2020 20:16 UTC | Cardiff Oncology, Inc. CRDF · Entity 6917 | PurchaseCommon Stock | 20,979 | $1.43 | $29,999.97 |
DisclosureSEC source: 0001104659-20-063181 · a4.xml · nonDerivative · entry 1 Markin Rodney S · CIK 0001393415 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · Fund Disclosed balance after: 28,160 F1 · ownership.nature: Through Prairie Ventures, LLC Read SEC document |
| June 20, 2019 Filed Jun 24, 2019 20:06 UTC | Cardiff Oncology, Inc. TROV · Entity 6917 | GrantStock Options · Derivative | 44,734 | $0.00 Strike: $2.48 | $0.00 |
DisclosureSEC source: 0000899243-19-017921 · doc4.xml · derivative · entry 1 Markin Rodney S · CIK 0001393415 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,969 Underlying: Common Stock · 44,734 shares Expires 2029-06-20 Read SEC document |
| June 20, 2018 Filed Jun 21, 2018 20:30 UTC | Cardiff Oncology, Inc. TROV · Entity 6917 | PurchaseCommon Stock | 41,200 | $0.85 | $35,020.00 |
DisclosureSEC source: 0000899243-18-017592 · doc4.xml · nonDerivative · entry 1 Markin Rodney S · CIK 0001393415 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 63,810 Read SEC document |
| June 20, 2018 Filed Nov 9, 2018 21:30 UTC Amendment | Cardiff Oncology, Inc. TROV · Entity 6917 | PurchaseCommon Stock | 41,200 | $0.85 | $35,020.00 |
DisclosureSEC source: 0000899243-18-028597 · doc4a.xml · nonDerivative · entry 1 Markin Rodney S · CIK 0001393415 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 43,085 Read SEC document |
| January 23, 2018 Filed Jan 25, 2018 22:02 UTC | Cardiff Oncology, Inc. TROV · Entity 6917 | GrantStock Options · Derivative | 54,322 | $0.00 Strike: $0.30 | $0.00 |
DisclosureSEC source: 0000899243-18-001905 · doc4.xml · derivative · entry 1 Markin Rodney S · CIK 0001393415 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 160,658 Underlying: Common Stock · 54,322 shares Expires 2028-01-23 Read SEC document |
| January 02, 2018 Filed Jan 4, 2018 22:15 UTC | Cardiff Oncology, Inc. TROV · Entity 6917 | Exercise / conversionRestricted Stock Units · Derivative | 16,667 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-18-000480 · doc4.xml · derivative · entry 2 Markin Rodney S · CIK 0001393415 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 16,667 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted stock unit is the economic equivalent of one share of Trovagene, Inc. common stock. F3 · derivative.exercise_date: On January 2, 2017, the reporting person was granted 16,667 restricted stock units, all of which vested on January 2, 2018. The common stock into which such vested restricted stock units converted on January 2, 2018 is reported in Table I on this Form 4. F3 · derivative.expiration_date: On January 2, 2017, the reporting person was granted 16,667 restricted stock units, all of which vested on January 2, 2018. The common stock into which such vested restricted stock units converted on January 2, 2018 is reported in Table I on this Form 4. Read SEC document |
| January 02, 2018 Filed Jan 4, 2018 22:15 UTC | Cardiff Oncology, Inc. TROV · Entity 6917 | Exercise / conversionCommon Stock | 16,667 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-18-000480 · doc4.xml · nonDerivative · entry 1 Markin Rodney S · CIK 0001393415 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,610 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Represents the conversion upon vesting of restricted stock units into common stock (the "Converted Common Stock"). On January 2, 2017, the reporting person was granted 16,667 restricted stock units, all of which vested on January 2, 2018. Such restricted stock units were previously reported in Table II on a Form 4 filed with the Securities and Exchange Commission on January 5, 2017. Read SEC document |
| October 04, 2017 Filed Oct 5, 2017 20:20 UTC | Cardiff Oncology, Inc. TROV · Entity 6917 | GrantStock Options · Derivative | 38,106 | $0.00 Strike: $0.72 | $0.00 |
DisclosureSEC source: 0001104659-17-061154 · a4.xml · derivative · entry 1 Markin Rodney S · CIK 0001393415 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 106,336 Underlying: Common Stock · 38,106 shares Expires 2027-10-04 Read SEC document |
| September 02, 2017 Filed Sep 7, 2017 00:40 UTC | Cardiff Oncology, Inc. TROV · Entity 6917 | Exercise / conversionRestricted Stock Units · Derivative | 5,943 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-17-055889 · a4.xml · derivative · entry 2 Markin Rodney S · CIK 0001393415 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,667 Underlying: Common Stock · 5,943 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted stock unit is the economic equivalent of one share of Trovagene, Inc. common stock. F3 · derivative.exercise_date: On January 2, 2017, the reporting person was granted 5,943 restricted stock units, all of which vested on September 2, 2017. The common stock into which such vested restricted stock units converted on September 2, 2017 is reported in Table I on this Form 4. F3 · derivative.expiration_date: On January 2, 2017, the reporting person was granted 5,943 restricted stock units, all of which vested on September 2, 2017. The common stock into which such vested restricted stock units converted on September 2, 2017 is reported in Table I on this Form 4. Read SEC document |
| September 02, 2017 Filed Sep 7, 2017 00:40 UTC | Cardiff Oncology, Inc. TROV · Entity 6917 | Exercise / conversionCommon Stock | 5,943 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-17-055889 · a4.xml · nonDerivative · entry 1 Markin Rodney S · CIK 0001393415 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,943 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Represents the conversion upon vesting of restricted stock units into common stock (the "Converted Common Stock"). On January 2, 2017, the reporting person was granted 5,943 restricted stock units, all of which vested on September 2, 2017. Such restricted stock units were previously reported in Table II on a Form 4 filed with the Securities and Exchange Commission on January 5, 2017. Read SEC document |
| January 02, 2017 Filed Jan 4, 2017 22:00 UTC | Cardiff Oncology, Inc. TROV · Entity 6917 | GrantRestricted Stock Units · Derivative | 16,667 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-17-000626 · a4.xml · derivative · entry 1 Markin Rodney S · CIK 0001393415 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,667 Underlying: Common Stock · 16,667 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit is the economic equivalent of one share of Trovagene, Inc. common stock. F2 · derivative.exercise_date: The RSUs shall vest on January 2, 2018. F2 · derivative.expiration_date: The RSUs shall vest on January 2, 2018. Read SEC document |
| January 02, 2017 Filed Jan 5, 2017 21:59 UTC Amendment | Cardiff Oncology, Inc. TROV · Entity 6917 | GrantRestricted Stock Units · Derivative | 5,943 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-17-000966 · a4a.xml · derivative · entry 2 Markin Rodney S · CIK 0001393415 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,610 Underlying: Common Stock · 5,943 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit is the economic equivalent of one share of Trovagene, Inc. common stock. F3 · derivative.exercise_date: The RSUs shall vest on September 2, 2017 F3 · derivative.expiration_date: The RSUs shall vest on September 2, 2017 Read SEC document |
| January 02, 2017 Filed Jan 5, 2017 21:59 UTC Amendment | Cardiff Oncology, Inc. TROV · Entity 6917 | GrantRestricted Stock Units · Derivative | 16,667 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-17-000966 · a4a.xml · derivative · entry 1 Markin Rodney S · CIK 0001393415 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,667 Underlying: Common Stock · 16,667 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit is the economic equivalent of one share of Trovagene, Inc. common stock. F2 · derivative.exercise_date: The RSUs shall vest on January 2, 2018. F2 · derivative.expiration_date: The RSUs shall vest on January 2, 2018. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.